UK Markets closed

Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market to Reach $44.6 Billion by 2027

·26-min read

Abstract: - Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market to Reach $44. 6 Billion by 2027. - Amid the COVID-19 crisis, the global market for Non-Small Cell Lung Cancer (NSCLC) Therapeutics estimated at US$20 Billion in the year 2020, is projected to reach a revised size of US$44.

New York, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Industry" - https://www.reportlinker.com/p06032349/?utm_source=GNW
6 Billion by 2027, growing at a CAGR of 12.1% over the analysis period 2020-2027. Targeted Therapy, one of the segments analyzed in the report, is projected to record a 11.9% CAGR and reach US$22.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Immunotherapy segment is readjusted to a revised 11.1% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $5.4 Billion, While China is Forecast to Grow at 16% CAGR
- The Non-Small Cell Lung Cancer (NSCLC) Therapeutics market in the U.S. is estimated at US$5.4 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$9.7 Billion by the year 2027 trailing a CAGR of 15.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.4% and 10.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 9.5% CAGR.
- Chemotherapy Segment to Record 13.8% CAGR
- In the global Chemotherapy segment, USA, Canada, Japan, China and Europe will drive the 13% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$3 Billion in the year 2020 will reach a projected size of US$7.1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$6.6 Billion by the year 2027, while Latin America will expand at a 15.4% CAGR through the analysis period.

- Select Competitors (Total 34 Featured) -

  • AstraZeneca

  • Boehringer Ingelheim

  • Bristol-Myers Squibb

  • Celgene Corp.

  • Eli Lilly and Company

  • F. Hoffmann-La Roche Ltd.

  • Genentech Inc.

  • GlaxoSmithKline plc

  • Novartis

  • Pfizer Inc.

  • Roche Holding AG

  • Sun Pharmaceutical Industries Ltd.




Read the full report: https://www.reportlinker.com/p06032349/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets for
Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Targeted Therapy
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 5: World Historic Review for Targeted Therapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Targeted Therapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Immunotherapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 8: World Historic Review for Immunotherapy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Immunotherapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Chemotherapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 11: World Historic Review for Chemotherapy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Chemotherapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Adenocarcinoma by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 14: World Historic Review for Adenocarcinoma by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Adenocarcinoma by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Squamous Cell
Carcinoma by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Squamous Cell Carcinoma by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Squamous Cell Carcinoma
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Large Cell
Carcinoma by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Large Cell Carcinoma by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Large Cell Carcinoma by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Kinase Inhibitor
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 23: World Historic Review for Kinase Inhibitor by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Kinase Inhibitor by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Microtubule
Stabilizer by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Microtubule Stabilizer by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Microtubule Stabilizer
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for PD-1 / PD-L1
Inhibitor by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 29: World Historic Review for PD-1 / PD-L1 Inhibitor by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 30: World 15-Year Perspective for PD-1 / PD-L1 Inhibitor
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 31: World Current & Future Analysis for Angiogenesis
Inhibitor by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 32: World Historic Review for Angiogenesis Inhibitor by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 33: World 15-Year Perspective for Angiogenesis Inhibitor
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 34: World Current & Future Analysis for Folate
Antimetabolites by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 35: World Historic Review for Folate Antimetabolites by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 36: World 15-Year Perspective for Folate Antimetabolites
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 37: World Current & Future Analysis for Epidermal Growth
Factor Receptor Blocker by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027 and % CAGR

Table 38: World Historic Review for Epidermal Growth Factor
Receptor Blocker by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 39: World 15-Year Perspective for Epidermal Growth Factor
Receptor Blocker by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 40: USA Current & Future Analysis for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 41: USA Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 42: USA 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Chemotherapy for the Years 2012, 2020 & 2027

Table 43: USA Current & Future Analysis for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma,
Squamous Cell Carcinoma and Large Cell Carcinoma - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 44: USA Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous
Cell Carcinoma and Large Cell Carcinoma Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 45: USA 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown
of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2012, 2020 & 2027

Table 46: USA Current & Future Analysis for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Drug Class - Kinase Inhibitor,
Microtubule Stabilizer, PD-1 / PD-L1 Inhibitor, Angiogenesis
Inhibitor, Folate Antimetabolites and Epidermal Growth Factor
Receptor Blocker - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 47: USA Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Drug Class - Kinase Inhibitor,
Microtubule Stabilizer, PD-1 / PD-L1 Inhibitor, Angiogenesis
Inhibitor, Folate Antimetabolites and Epidermal Growth Factor
Receptor Blocker Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 48: USA 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Drug Class - Percentage
Breakdown of Value Sales for Kinase Inhibitor, Microtubule
Stabilizer, PD-1 / PD-L1 Inhibitor, Angiogenesis Inhibitor,
Folate Antimetabolites and Epidermal Growth Factor Receptor
Blocker for the Years 2012, 2020 & 2027

CANADA
Table 49: Canada Current & Future Analysis for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 50: Canada Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 51: Canada 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Chemotherapy for the Years 2012, 2020 & 2027

Table 52: Canada Current & Future Analysis for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma,
Squamous Cell Carcinoma and Large Cell Carcinoma - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 53: Canada Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous
Cell Carcinoma and Large Cell Carcinoma Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 54: Canada 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown
of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2012, 2020 & 2027

Table 55: Canada Current & Future Analysis for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Drug Class - Kinase
Inhibitor, Microtubule Stabilizer, PD-1 / PD-L1 Inhibitor,
Angiogenesis Inhibitor, Folate Antimetabolites and Epidermal
Growth Factor Receptor Blocker - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 56: Canada Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Drug Class - Kinase Inhibitor,
Microtubule Stabilizer, PD-1 / PD-L1 Inhibitor, Angiogenesis
Inhibitor, Folate Antimetabolites and Epidermal Growth Factor
Receptor Blocker Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 57: Canada 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Drug Class - Percentage
Breakdown of Value Sales for Kinase Inhibitor, Microtubule
Stabilizer, PD-1 / PD-L1 Inhibitor, Angiogenesis Inhibitor,
Folate Antimetabolites and Epidermal Growth Factor Receptor
Blocker for the Years 2012, 2020 & 2027

JAPAN
Table 58: Japan Current & Future Analysis for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 59: Japan Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 60: Japan 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Chemotherapy for the Years 2012, 2020 & 2027

Table 61: Japan Current & Future Analysis for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma,
Squamous Cell Carcinoma and Large Cell Carcinoma - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 62: Japan Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous
Cell Carcinoma and Large Cell Carcinoma Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 63: Japan 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown
of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2012, 2020 & 2027

Table 64: Japan Current & Future Analysis for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Drug Class - Kinase
Inhibitor, Microtubule Stabilizer, PD-1 / PD-L1 Inhibitor,
Angiogenesis Inhibitor, Folate Antimetabolites and Epidermal
Growth Factor Receptor Blocker - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 65: Japan Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Drug Class - Kinase Inhibitor,
Microtubule Stabilizer, PD-1 / PD-L1 Inhibitor, Angiogenesis
Inhibitor, Folate Antimetabolites and Epidermal Growth Factor
Receptor Blocker Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 66: Japan 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Drug Class - Percentage
Breakdown of Value Sales for Kinase Inhibitor, Microtubule
Stabilizer, PD-1 / PD-L1 Inhibitor, Angiogenesis Inhibitor,
Folate Antimetabolites and Epidermal Growth Factor Receptor
Blocker for the Years 2012, 2020 & 2027

CHINA
Table 67: China Current & Future Analysis for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 68: China Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 69: China 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Chemotherapy for the Years 2012, 2020 & 2027

Table 70: China Current & Future Analysis for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma,
Squamous Cell Carcinoma and Large Cell Carcinoma - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 71: China Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous
Cell Carcinoma and Large Cell Carcinoma Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 72: China 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown
of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2012, 2020 & 2027

Table 73: China Current & Future Analysis for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Drug Class - Kinase
Inhibitor, Microtubule Stabilizer, PD-1 / PD-L1 Inhibitor,
Angiogenesis Inhibitor, Folate Antimetabolites and Epidermal
Growth Factor Receptor Blocker - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 74: China Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Drug Class - Kinase Inhibitor,
Microtubule Stabilizer, PD-1 / PD-L1 Inhibitor, Angiogenesis
Inhibitor, Folate Antimetabolites and Epidermal Growth Factor
Receptor Blocker Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 75: China 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Drug Class - Percentage
Breakdown of Value Sales for Kinase Inhibitor, Microtubule
Stabilizer, PD-1 / PD-L1 Inhibitor, Angiogenesis Inhibitor,
Folate Antimetabolites and Epidermal Growth Factor Receptor
Blocker for the Years 2012, 2020 & 2027

EUROPE
Table 76: Europe Current & Future Analysis for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Geographic Region - France,
Germany, Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 77: Europe Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 78: Europe 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Geographic Region - Percentage
Breakdown of Value Sales for France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets for Years 2012, 2020 & 2027

Table 79: Europe Current & Future Analysis for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 80: Europe Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 81: Europe 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Chemotherapy for the Years 2012, 2020 & 2027

Table 82: Europe Current & Future Analysis for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma,
Squamous Cell Carcinoma and Large Cell Carcinoma - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 83: Europe Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous
Cell Carcinoma and Large Cell Carcinoma Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 84: Europe 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown
of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2012, 2020 & 2027

Table 85: Europe Current & Future Analysis for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Drug Class - Kinase
Inhibitor, Microtubule Stabilizer, PD-1 / PD-L1 Inhibitor,
Angiogenesis Inhibitor, Folate Antimetabolites and Epidermal
Growth Factor Receptor Blocker - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 86: Europe Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Drug Class - Kinase Inhibitor,
Microtubule Stabilizer, PD-1 / PD-L1 Inhibitor, Angiogenesis
Inhibitor, Folate Antimetabolites and Epidermal Growth Factor
Receptor Blocker Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 87: Europe 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Drug Class - Percentage
Breakdown of Value Sales for Kinase Inhibitor, Microtubule
Stabilizer, PD-1 / PD-L1 Inhibitor, Angiogenesis Inhibitor,
Folate Antimetabolites and Epidermal Growth Factor Receptor
Blocker for the Years 2012, 2020 & 2027

FRANCE
Table 88: France Current & Future Analysis for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 89: France Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 90: France 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Chemotherapy for the Years 2012, 2020 & 2027

Table 91: France Current & Future Analysis for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma,
Squamous Cell Carcinoma and Large Cell Carcinoma - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 92: France Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous
Cell Carcinoma and Large Cell Carcinoma Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 93: France 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown
of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2012, 2020 & 2027

Table 94: France Current & Future Analysis for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Drug Class - Kinase
Inhibitor, Microtubule Stabilizer, PD-1 / PD-L1 Inhibitor,
Angiogenesis Inhibitor, Folate Antimetabolites and Epidermal
Growth Factor Receptor Blocker - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 95: France Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Drug Class - Kinase Inhibitor,
Microtubule Stabilizer, PD-1 / PD-L1 Inhibitor, Angiogenesis
Inhibitor, Folate Antimetabolites and Epidermal Growth Factor
Receptor Blocker Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 96: France 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Drug Class - Percentage
Breakdown of Value Sales for Kinase Inhibitor, Microtubule
Stabilizer, PD-1 / PD-L1 Inhibitor, Angiogenesis Inhibitor,
Folate Antimetabolites and Epidermal Growth Factor Receptor
Blocker for the Years 2012, 2020 & 2027

GERMANY
Table 97: Germany Current & Future Analysis for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 98: Germany Historic Review for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 99: Germany 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Chemotherapy for the Years 2012, 2020 & 2027

Table 100: Germany Current & Future Analysis for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma,
Squamous Cell Carcinoma and Large Cell Carcinoma - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 101: Germany Historic Review for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma,
Squamous Cell Carcinoma and Large Cell Carcinoma Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 102: Germany 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown
of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2012, 2020 & 2027

Table 103: Germany Current & Future Analysis for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Drug Class - Kinase
Inhibitor, Microtubule Stabilizer, PD-1 / PD-L1 Inhibitor,
Angiogenesis Inhibitor, Folate Antimetabolites and Epidermal
Growth Factor Receptor Blocker - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 104: Germany Historic Review for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Drug Class - Kinase Inhibitor,
Microtubule Stabilizer, PD-1 / PD-L1 Inhibitor, Angiogenesis
Inhibitor, Folate Antimetabolites and Epidermal Growth Factor
Receptor Blocker Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 105: Germany 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Drug Class - Percentage
Breakdown of Value Sales for Kinase Inhibitor, Microtubule
Stabilizer, PD-1 / PD-L1 Inhibitor, Angiogenesis Inhibitor,
Folate Antimetabolites and Epidermal Growth Factor Receptor
Blocker for the Years 2012, 2020 & 2027

ITALY
Table 106: Italy Current & Future Analysis for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 107: Italy Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 108: Italy 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Chemotherapy for the Years 2012, 2020 & 2027

Table 109: Italy Current & Future Analysis for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma,
Squamous Cell Carcinoma and Large Cell Carcinoma - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 110: Italy Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous
Cell Carcinoma and Large Cell Carcinoma Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 111: Italy 15-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown
of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2012, 2020 & 2027

Table 112: Italy Current & Future Analysis for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Drug Class - Kinase
Inhibitor, Microtubule Stabilizer, PD-1 / PD-L1 Inhibitor,
Angiogenesis Inhibitor, Folate Antimetabolites and Epidermal
Growth Factor Receptor Blocker - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 113: Italy Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Drug Class - Kinase Inhibitor,
Microtubule Stabilizer, PD-1 / PD-L1 Inhibitor, Angiogenesis
Inhibitor, Folate Antimetabolites and Epidermal Growth Factor
Receptor Blocker Markets - Independent Analysis of Annual Sales

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06032349/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting